secwatch.observer — SEC 8-K summary
======================================

Issuer:     INSMED Inc (INSM)
CIK:        0001104506
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0001140361-23-008163
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Insmed reports Q4 2022 ARIKAYCE revenue $59.3M, full year $245.4M; net loss $1.21 per share
--------------------------------------------------------------------------------

- ARIKAYCE global revenue grew 30% in 2022 to $245.4M; Q4 revenue $59.3M, impacted by $7.5M French pricing adjustment.
- Net loss for Q4 2022 was $160.1M ($1.21/share) vs $113.0M ($0.95/share) in Q4 2021; full year net loss $481.5M ($3.91/share).
- Phase 3 ASPEN trial of brensocatib in bronchiectasis completed adult patient screening; topline data expected Q2 2024.
- Company guides 2023 ARIKAYCE global revenue $285-300M; cash position $1.15B as of Dec 31, 2022.
- ARISE study topline data expected Q3 2023; ENCORE enrollment by end 2023; early-stage research update May 8, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1104506/000114036123008163/0001140361-23-008163-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1104506/000114036123008163/brhc10048554_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-008163

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer